ImmunityBio (IBRX) Shares Outstanding (2014 - 2026)

ImmunityBio (IBRX) has reported Shares Outstanding (Entity) for 13 consecutive years, with $1.0 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Shares Outstanding (Entity) rose 22.7% year-over-year to $1.0 billion; the TTM figure through Mar 2026 stood at $1.0 billion (up 22.7% YoY), while the FY2025 annual figure was $1.0 billion, up 45.1% from the prior year.
• Shares Outstanding (Entity) rose to $1.0 billion in Q1 2026 per IBRX's latest filing, from $1.0 billion in the prior quarter.
• Across five years, Shares Outstanding (Entity) topped out at $1.0 billion in Q1 2026 and bottomed at $398.0 million in Q1 2022.
• Historically, Shares Outstanding (Entity) has averaged $652.5 million across 5 years, with a median of $677.0 million in 2024.
• Annual changes were most pronounced in 2022 — Shares Outstanding (Entity) grew 1.47% — and 2024, when it jumped 56.99%.
• ImmunityBio's Shares Outstanding (Entity) stood at $435.9 million in 2022, then advanced by 16.68% to $508.6 million in 2023, then surged by 37.09% to $697.3 million in 2024, then jumped by 45.1% to $1.0 billion in 2025, then increased by 3.51% to $1.0 billion in 2026.
• Business Quant data shows IBRX's Shares Outstanding (Entity) at $1.0 billion in Q1 2026, $1.0 billion in Q4 2025, and $985.0 million in Q3 2025.